全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Review: DRUG PRICE COMPETITION AND PATENT TERM RESTORATION ACT, 1984 AND THIRTY-MONTH STAY PROVISION

Keywords: New drug application , Federal trade commission , ANDA: Abbreviated new drug application , FDA.

Full-Text   Cite this paper   Add to My Lib

Abstract:

The Hatch-Waxman act of 1984 has been quite successful in increasing the availability of generic drugs, but closer analysis reveals that the Act’s provisions relating to patent certification actually delay approval of generic drugs. The following paper addresses the problems arising from the thirty-month stay provision of the Hatch-Waxman Act, evaluates the legitimacy of the provision under accepted philosophical justifications for intellectual property, and suggests possible alternatives for addressing the failures of this provision. This article interprets the complicated Act and examines it with respect to the different theories of intellectual property. The numerous problems caused by the thirty month stay provision, ‘evergreening’ and ‘trip-wire’ patenting are also discussed at length. The legal implications of litigation including ethics and anti-trust law are examined. In conclusion, we authors recommend various remedial steps to be taken to exploit the Act to its fullest such that generic drug approval is not unnecessarily delayed.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133